Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04403763 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT04403763 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 80 participants.
The verdict
NCT04403763, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants
Interventions
- DRUG Vehicle
- DRUG AGN-241622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2022-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04403763
The ClinicalTrials.gov registry entry for NCT04403763 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04403763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04403763 about?
NCT04403763 is a clinical study titled "Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia". The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants
What is the current status of trial NCT04403763?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2020-07-27. Estimated completion is 2022-12-05.
What interventions are being tested in trial NCT04403763?
The interventions under investigation include: Vehicle (DRUG), AGN-241622 (DRUG).
Who is sponsoring clinical trial NCT04403763?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.